A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)

PHASE2CompletedINTERVENTIONAL
Enrollment

356

Participants

Timeline

Start Date

July 19, 2017

Primary Completion Date

September 19, 2018

Study Completion Date

September 19, 2018

Conditions
MenopauseHot Flashes
Interventions
DRUG

Fezolinetant

Oral Capsule

DRUG

Placebo

Oral Capsule

Trial Locations (51)

10032

Research Site, New York

14221

Research Site, Williamsville

19140

Research Site, Philadelphia

21075

Research Site, Elkridge

22182

Research Site, Vienna

22911

Research Site, Charlottesville

29464

Research Site, Mt. Pleasant

30092

Research Site, Norcross

30312

Research Site, Atlanta

32174

Research Site, Ormond Beach

32720

Research Site, DeLand

33144

Research Site, Miami

33458

Research Site, Jupiter

33461

Research Site, Lake Worth

34429

Research Site, Crystal River

34952

Research Site, Port Saint Lucie

35205

Research Site, Birmingham

36207

Research Site, Anniston

37040

Research Site, Clarksville

37660

Research Site, Kingsport

43210

Research Site, Columbus

43213

Research Site, Columbus

44122

Research Site, Cleveland

45267

Research Site, Cincinnati

61820

Research Site, Champaign

68510

Research Site, Lincoln

68701

Research Site, Norfolk

70072

Research Site, Marrero

73112

Research Site, Oklahoma City

75093

Research Site, Plano

76054

Research Site, Hurst

76550

Research Site, Lampasas

77058

Research Site, Houston

78229

Research Site, San Antonio

80209

Research Site, Denver

83642

Research Site, Meridian

84065

Research Site, Riverton

85023

Research Site, Phoenix

89123

Research Site, Las Vegas

90057

Research Site, Los Angeles

91360

Research Site, Thousand Oaks

91402

Research Site, Panorama City

91607

Research Site, Valley Village

92056

Research Site, Oceanside

92114

Research Site, San Diego

95821

Research Site 052, Sacramento

Research Site 058, Sacramento

98105

Research Site, Seattle

99207

Research Site, Spokane

06460

Research Site, Milford

02472

Research Site, Watertown

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT03192176 - A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes) | Biotech Hunter | Biotech Hunter